- Can-Fite Updates on Status of Phase II Advanced Liver Cancer Trial
- Can-Fite Reports on New Pre-Clinical Developments with Its NASH Drug Namodenoson
- Can-Fite to Present the Anti-Inflammatory and Anti-Fibrogenic Effects of Namodenoson in NAFLD/NASH Pre-clinical Studies at the 2018 International Liver Congress of the European Association for the Study of the Liver (EASL)
- Can-Fite to Present at the MicroCap Conference
Can Fite Biopharma Ltd (CANF:TLV) closed at 242.10, 10.05% above the 52 week low of 220.00 set on Dec 18, 2017.
220.00Dec 18 2017432.80Jan 30 2018
|Market cap||95.02m ILS|
|EPS (TTM)||-0.5635 |
Data delayed at least 20 minutes, as of Jun 21 2018 15:24 BST.